Liliana Elena Weimer | Medicine and Health Sciences | Best Researcher Award

Published on by Top Teachers

Best Researcher Award

Liliana Elena Weimer
Italian National Institute of Health, Italy
Liliana Elena Weimer
Affiliation Italian National Institute of Health
Country Italy
Google Scholar 2q3g0CAAAAAJ
Documents 128
Citations 2,534
h-index 22
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
Scopus ID 6701388312
ORCID 0000-0002-1554-3150

Liliana Elena Weimer is a medical doctor and clinical researcher with over 30 years of experience in infectious diseases, clinical trials, and global health. Since 2022 she serves as First Researcher (Level II) at the Center for Global Health – Istituto Superiore di Sanità (ISS), Rome, Italy. Her career spans landmark HIV/HCV studies, COVID‑19 surveillance, Long‑COVID coordination, and international collaborations with WHO, the G20, and the American Clinical Trials Group.[1][2]

She has participated in national and multinational cohort studies, public health surveillance programs, and clinical research initiatives focused on infectious diseases and global health. As of September 2026, she has authored or co-authored more than 177 scientific publications and has contributed to research programs involving the American Clinical Trials Group, European collaborative projects, WHO-related activities, and Italian national surveillance systems. Her scholarly profile reflects sustained engagement in evidence-based medicine, public health research, and clinical investigation across several decades.[1][2]

Abstract

This article presents the academic and research profile of Dr. Liliana Elena Weimer, nominated for the Best Researcher Award in recognition of her outstanding contributions to clinical virology, public health surveillance, and international collaborative research. With a career spanning more than three decades at the Italian National Institute of Health (ISS), Dr. Weimer has coordinated national and multinational trials on HIV and HCV, contributed to the PITER cohort (25,000 patients), and led COVID‑19 and Long‑COVID surveillance protocols. Her work is characterised by high‑impact publications, a consistent h‑index of 22, and active engagement in European projects (ORCHESTRA, PREVENT Horizon, SHIELD). The nomination is supported by her record of public competition successes, teaching, and service with Doctors Without Borders.[1]

Keywords

Best Researcher Award, HIV/HCV clinical trials, PITER cohort, COVID‑19 surveillance, Long‑COVID, Malattie Infettive Long Covid, Doctor in Medicine, Infectious Diseases.

Introduction

The Best Researcher Award recognises individuals who demonstrate exceptional scientific output, leadership, and translational impact. Liliana Elena Weimer, MD, has built a distinguished career at the Istituto Superiore di Sanità (ISS), where she has been instrumental in shaping infectious disease research in Italy and beyond. Her work encompasses antiretroviral therapy optimisation, hepatitis C elimination strategies, and the establishment of national surveillance systems for HIV, HCV, and SARS‑CoV‑2. Notably, she is a member of the ISS COVID‑19 National Surveillance Group and the PITER study coordination team, and she contributes to WHO guidelines on Long‑Covid. Her international collaborations and sustained publication record make her a strong candidate for this award.[3]

Research Profile

Dr. Liliana Elena Weimer holds a medical degree from the University of Buenos Aires and a second MD from the University of L’Aquila, with specialisations in Infectious Diseases and Clinical Pharmacology. She has been a researcher at ISS since 1990, winning public competitions for fixed‑term, permanent, and First Researcher positions. Her research profile is characterised by a strong commitment to clinical epidemiology and trial methodology. She has contributed to landmark studies such as ACTG 384/388 (Italy‑USA AIDS trials), the PITER HCV cohort, and the European ORCHESTRA project. She also coordinates the national Long‑COVID surveillance protocol (2021‑2026) funded by the Italian Ministry of Health. With over 128 documents, 2,534 citations, and an h‑index of 22 (Scopus), she maintains a visible presence in the field.[2][4]

  • Senior Clinical Researcher at the Italian National Institute of Health (ISS), Rome.
  • More than three decades of experience in multicenter clinical trials and epidemiological research.
  • Collaborator with international HIV and HCV research networks.
  • Contributor to national SARS-CoV-2 and Long COVID surveillance programs.
  • Participant in European collaborative projects including ORCHESTRA, PREVENT Horizon, SHIELD, EURO-PERISTAT, and JA-05.
  • Member of professional organizations focused on infectious diseases and public health.

Research Contributions

Dr. Liliana Elena Weimer’s contributions are organised around three pillars: clinical trials and cohort studies, public health surveillance, and global health collaborations. She has coordinated over twenty national and international multicentre trials, including the Italian Protease Inhibitors Registry and the NIA surveillance network. As part of the PITER study, she contributed to the largest Italian HCV cohort (25,000 patients), informing treatment strategies for cirrhosis and hepatocellular carcinoma. During the COVID‑19 pandemic, she joined the ISS national surveillance group and collaborated with Bambino Gesù Pediatric Hospital, providing clinical and epidemiological support. She also serves as an external consultant for WHO’s Long‑Covid guidelines and is a member of the Brussels Network of Expertise on Long‑Covid.[5]

Liliana Elena Weimer’s research portfolio encompasses HIV treatment optimization, hepatitis C management, SARS-CoV-2 surveillance, and Long COVID characterization. Her participation in national cohort studies and international clinical trials has contributed to understanding treatment effectiveness, patient outcomes, and disease epidemiology.[1][3]

  • Clinical trials and cohort studies involving HIV therapies.
  • Research on HCV treatment outcomes and long-term virological response.
  • Investigation of monoclonal antibody strategies against emerging SARS-CoV-2 variants.
  • Long COVID symptom characterization and longitudinal follow-up studies.
  • Public health surveillance and antimicrobial resistance research.
  • Support for healthcare access initiatives in resource-limited settings.

Publications

Dr. Liliana Elena Weimer has authored or co‑authored more than 120 peer‑reviewed articles, book chapters, and monographs. Her work appears in high‑impact journals including Hepatology, Children, and Journal of Pediatrics Research Reviews. She received the Best Research Award from the journal Children (IF 2.5) for a study on the clinical characterisation of adolescents with Long‑COVID. She has also published two books on post‑COVID sequelae and SARS‑CoV‑2 variants. Below is a selection of her most cited works:

  • Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, … Weimer LE (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3):833‑844.
  • George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, … Weimer LE (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3):729‑738.
  • Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, … Weimer LE (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3):715‑725.

Research Impact

With over 2,534 citations and an h‑index of 22, Dr. Liliana Elena Weimer’s work has shaped clinical practice in hepatitis C and HIV care. Her studies on sustained virologic response and long‑term outcomes after HCV therapy are frequently cited in guidelines. She has received multiple recognitions, including an Abstract of Distinction at the AASLD Liver Meeting (2018) and the 2025 Best Research Award from Children journal. She was a Special Invitee to the G20 Health Summit 2023 and serves as a lay judge at the Court of Assizes in Rome. Her impact extends beyond academia: she is a volunteer with Doctors Without Borders (since 1992), providing AIDS therapies in Brazil, and actively participates in public health emergency responses.[1][3]

Award Suitability

The Best Researcher Award recognises sustained excellence, and Dr. Liliana Elena Weimer’s trajectory exemplifies this. She has won three public competitions at the ISS (fixed‑term, permanent, and First Researcher), demonstrating peer‑reviewed career progression. She coordinates the national PITER HCV cohort and the Long‑COVID surveillance protocol, and she has contributed to WHO guidelines. Her publication record includes landmark articles in hepatology, and she has received journal‑level awards for her work on Long‑COVID. Her international collaborations with the American Clinical Trials Group, INSERM, and the European Commission place her among the leading clinical researchers in Italy. This award would further acknowledge her role in translating research into public health action.[4]

Conclusion

Dr. Liliana Elena Weimer is a medical researcher of high calibre, with a career that bridges clinical trials, epidemiological surveillance, and global health equity. Her work on HIV, HCV, and COVID‑19 has informed national and international guidelines, and her commitment to service—through Doctors Without Borders and public health emergencies—distinguishes her as a compassionate and effective leader. The data presented—128 documents, 2,534 citations, h‑index 22, and consistent recognition—support her nomination for the Best Researcher Award. Her profile aligns with the core values of the award: scientific rigor, translational impact, and dedication to improving human health.[5]

References

  1. Scopus. (n.d.). Author details: Weimer, Liliana Elena, Author ID 6701388312. Scopus Preview.https://www.scopus.com/pages/authors/6701388312
  2. Google Scholar. (n.d.). Liliana Elena Weimer – citations & h‑index. Google Scholar.https://scholar.google.co.uk/citations?user=2q3g0CAAAAAJ
  3. Morgan, T. R., Ghany, M. G., Kim, H. Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., … & Weimer, L. E. (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3), 833‑844. https://doi.org/10.1002/hep.23744
  4. George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J., … & Weimer, L. E. (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3), 729‑738. https://doi.org/10.1002/hep.22694
  5. Saxena, V., Nyberg, L., Pauly, M., Dasgupta, A., Nyberg, A., Piasecki, B., … & Weimer, L. E. (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3), 715‑725. https://doi.org/10.1002/hep.27922

Song Guo Zheng | Medicine and Health Sciences | Best Innovator Award

Published on by Top Teachers

Best Innovator Award

Song Guo Zheng
Shanghai Jiao Tong University, China
Song Guo Zheng
Affiliation Shanghai Jiao Tong University
Country China
Scopus ID 7403146499
Documents 262
Citations 16,675
h-index 75
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
ORCID 0000-0002-5611-4774
Google Scholar 37kvQ18AAAAJ

Song Guo Zheng is a physician-scientist and immunologist whose academic career has spanned molecular immunology, rheumatology, autoimmunity, cell therapy, and translational medicine. His research has contributed to the understanding of regulatory T cells, immune tolerance, autoimmune disease mechanisms, and therapeutic immunomodulation. He currently serves as Chair Professor of Medicine and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University School of Medicine while maintaining extensive leadership roles in international scientific organizations and scholarly publishing.[1]

Abstract

This article evaluates the academic achievements, scientific leadership, educational service, and innovation record of Song Guo Zheng in relation to the Best Innovator Award. His work integrates fundamental immunology with translational medicine, resulting in influential publications, patents, edited books, international collaborations, and leadership positions across major scientific societies. The breadth of his contributions demonstrates sustained impact on biomedical research and clinical immunology.[1]

Keywords

Rheumatology, Immunology, Autoimmunity, T Regulatory Cells, Cell Therapy, GMSC, Tumor Immunity.

Introduction

Over several decades, Song Guo Zheng has established an interdisciplinary research program focused on immune regulation, autoimmune disease pathogenesis, regenerative medicine, and therapeutic cell engineering. His academic development includes medical training in China, doctoral education in France, and faculty appointments at major institutions in the United States and China. His scientific output has contributed to both theoretical and applied aspects of immunological science.[1]

Research Profile

Song Guo Zheng earned an M.D. from Anhui Medical University and later completed a Ph.D. in Molecular Immunology at the University of Orleans, France. His academic appointments have included leadership roles at the University of Southern California, Penn State University, Ohio State University, and Shanghai Jiao Tong University. He has also served as editor, associate editor, and editorial board member for numerous high-impact journals while participating in major international grant-review panels and scientific committees.[1]

Research Contributions

  • Advanced understanding of regulatory T-cell biology and immune tolerance mechanisms.[2]
  • Developed strategies for immune modulation relevant to autoimmune disorders and inflammatory diseases.[3]
  • Contributed to translational research in cell therapy, tumor immunity, and regenerative medicine.
  • Secured multiple granted patents involving regulatory T cells, exosome applications, and immunotherapeutic technologies.[1]
  • Edited scientific books and chapters that support education and dissemination of immunological knowledge.

Publications

Representative publications include influential studies on regulatory T-cell induction, immune tolerance, vitamin-mediated immune regulation, and chronic disease immunobiology. These works have become widely cited within immunology and rheumatology literature.[2][3][4][5][6]

Research Impact

According to the provided scholarly metrics, the researcher has produced 262 indexed documents, accumulated more than 16,675+ citations, and achieved an h-index of 75. These indicators reflect substantial scholarly visibility and influence within biomedical sciences. His leadership in international societies, conference organization, editorial service, and research mentoring further extends the impact of his work beyond publication metrics alone.[1]

Award Suitability

The Best Innovator Award recognizes individuals who demonstrate sustained innovation, measurable research impact, educational leadership, and translational achievement. Song Guo Zheng’s portfolio includes pioneering immunological discoveries, numerous patents, extensive publication activity, scientific leadership, international recognition, and contributions to medical education. These accomplishments collectively support strong consideration for recognition within innovation-focused academic award programs.[1]

Conclusion

Song Guo Zheng has developed a distinguished career characterized by innovation in immunology, leadership in academic medicine, and contributions to translational biomedical research. His scientific achievements, educational service, publication record, patents, and international professional engagement provide a substantial foundation for recognition under the Best Innovator Award framework.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Song Guo Zheng, Author ID 7403146499. Scopus. https://www.scopus.com/authid/detail.uri?authorId=7403146499
  2. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and Induced CD4+CD25+ Cells Educate CD4+CD25− Cells to Develop Suppressive Activity. The Journal of Immunology. https://doi.org/10.4049/jimmunol.172.9.5213
  3. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of Vitamin A in the Immune System. Journal of Clinical Medicine. https://doi.org/10.3390/jcm7090258
  4. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.178.4.2018
  5. Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA. Generation Ex Vivo of TGF-β-Producing Regulatory T Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.169.8.4183
  6. Wang H, Chen W, Li D, Yin X, Zhang X, Olsen N, Zheng SG. Vitamin D and Chronic Diseases. Aging and Disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC5440113/

Adrianna Lebiedzińska | Low-Triiodothyronine Syndrome | Research Excellence Award

Published on by Top Teachers

Dr. Adrianna Lebiedzińska | Low-Triiodothyronine Syndrome | Research Excellence Award

University Clinical Hospital in Wroclaw | Poland

Dr. Adrianna Łebiedzińska, MD, is a resident in anesthesiology and intensive care at the University Clinical Hospital in Wrocław, Poland, specializing in neurocritical care. Her research focuses on metabolic and endocrine disturbances following acute brain injury, particularly aneurysmal subarachnoid hemorrhage. She has contributed to advancing prognostic assessment through her work on low triiodothyronine (T3) syndrome, including the development of a novel reference-adjusted FT3 metric that improved predictive model performance. Dr. Łebiedzińska has published in Biomedicines (2026) and actively collaborates with multidisciplinary clinical research teams at Wrocław Medical University. A member of the Polish Society of Anaesthesiology and Intensive Therapy, her work aims to enhance clinical decision-making and patient outcomes in critically ill neurological populations, reflecting a strong commitment to translational research and healthcare impact.

ORCID

Featured Publications

A Lebiedzińska, M Burzyńska, J Woźniak, W Goździk (2026).
The Prognostic Significance of Low-Triiodothyronine Syndrome in Aneurysmal Subarachnoid Hemorrhage
Biomedicines | Journal Article · 2026 · DOI: 10.3390/biomedicines14030603

M Burzyńska, J Woźniak, A Uryga, A Lebiedzińska, M Kasprowicz, W Goździk (2022).
Wpływ wczesnego uszkodzenia mózgu na rozwój wtórnego niedokrwienia i wczesny wynik leczenia chorych po krwotoku podpajęczynówkowym z pękniętego tętniaka
Forum Zakażeń | Conference Paper · 2022

A Lebiedzińska, A Uryga, M Burzyńska (2022).
Zaburzenia ogólnoustrojowe w ostrej fazie u chorych z patologią wewnątrzczaszkową – opis przypadku
Wrocławska Wiosna Anestezjologiczna | Conference Paper · 2022

A Lebiedzińska, A Uryga, M Burzyńska (2022).
Zaburzenia ogólnoustrojowe w ostrej fazie u chorych z patologią wewnątrzczaszkową – opis przypadku
Wrocławska Wiosna Anestezjologiczna | Conference Poster · 2022

Mohammad Uddin | Medicine and Health Sciences | Research Excellence Award

Published on by Top Teachers

Dr. Mohammad Uddin | Medicine and Health Sciences | Research Excellence Award

Hamamatsu University School of Medicine | Bangladesh

Dr. Mohammad Khaja Mafij Uddin is an Associate Scientist in the Infectious Diseases Division at icddr,b, with over 15 years of expertise in mycobacteriology and tuberculosis (TB) diagnostics. His work integrates molecular, microbiological, and immunological approaches to advance TB detection, drug resistance analysis, and biomarker discovery. He has led and contributed to multiple internationally funded projects, including collaborations with organizations in France, Korea, and the USA, focusing on innovative diagnostics such as targeted next-generation sequencing and non-respiratory TB detection. Dr. Uddin has authored several peer-reviewed publications in high-impact journals, contributing significantly to understanding TB transmission dynamics and extrapulmonary TB. He has mentored graduate students and strengthened laboratory capacity, with his research directly supporting improved TB diagnosis and public health outcomes in high-burden settings.

Citation Metrics (Scopus)

94
75
50
25
0

Citations
94

h-index
4

Documents
5

Citations

h-index

Documents

Featured Publications

Liu Wenyi | Health Sciences | Best Researcher Award

Published on by Top Teachers

Dr. Liu Wenyi | Health Sciences | Best Researcher Award

Cancer Hospital Chinese Academy of Medical Sciences | China

Dr. Liu Wenyi is a thoracic-surgery specialist whose research focuses on advanced treatments for thoracic malignancies especially esophageal and lung cancers emphasising organ-preservation strategies, neoadjuvant chemo-/chemo-immunotherapy, imaging- and machine-learning-based response assessment, and translational biomarkers for surgical decision-making. His work has contributed to the evolving paradigm of less-invasive surgery and more personalised multimodal care. For example, his recent narrative review “Organ Preservation in Esophageal Cancer: Current Strategies, Challenges, and Future Directions” is a state-of-the-field synthesis published in Cancers  highlighting novel surveillance-based approaches in esophageal squamous cell carcinoma. His Google Scholar/Scopus profile indicates approximately 10 publications and a current h-index of 5 (citations ~80) under his name. This volume reflects a mid-career emerging investigator whose trajectory is marked by high-impact topics (thoracic oncology, immunotherapy, AI-enabled imaging) and whose top publications already appear in high-visibility journals. Dr. Liu’s work is characterized by integrating minimally invasive surgical techniques, cutting-edge neoadjuvant systemic treatments and advanced predictive modelling to stratify patients for surgical risk and organ-sparing pathways thus contributing to both improved patient quality of life and optimized oncologic outcomes.His outstanding contributions to clinical innovation and scientific research excellence reflect strong merit for recognition under the Best Researcher Award .

Publication Profile

Orcid

Featured Publications

Liu, W., Guo, X., Zhao, H., Yu, X., Wang, C., Du, L., Wang, F., & Mu, J. (2020). Mediastinoscopy-assisted transhiatal esophagectomy versus thoraco-laparoscopic esophagectomy for esophageal cancer: A single-center initial experience. Journal of Thoracic Disease, 12(9), 4908-4914.

Liu, W., Tang, J., Li, X., Gong, L., Yang, D., Yin, H., Wang, W., & Zhang, B. (2025). Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non-small cell lung cancer. Oncology Letters, 30(5), 501.

Liu, W., Sui, Z., Wang, C., Deng, Y., Cai, S., Jia, R., Yu, Z., Kang, M., & Zhang, B. (2025). Nomogram for predicting pathological complete response to neoadjuvant chemoimmunotherapy in patients with resectable non-small cell lung cancer. Frontiers in Cell and Developmental Biology, 13, 1679782.

Hong, Z., Xie, S., Xu, H., Ke, S., Liu, W., Huang, S., Chen, S., Xie, J., Xu, J., & Kang, M. (2025). Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study. European Journal of Surgical Oncology, 51(2), 109500.

Liu, W., Zhang, B., Wang, C., Yu, X., Du, L., Yu, Z., & Kang, M. (2025). Organ Preservation in Esophageal Cancer: Current Strategies, Challenges, and Future Directions. Cancers, 17(21), 3559.

 

EMMANUEL SCALAIS | Medicine and Health Sciences | Outstanding Scientist Award

Published on by Top Teachers

Dr.EMMANUELSCALAIS|MedicineandHealth Sciences| Outstanding Scientist Award

MD at NEPE, Luxembourg.

Dr. Emmanuel Scalais is the Chief Physician of the Pediatric Neurology Department at Centre Hospitalier de Luxembourg (CHL)He has authored 82 publications and has been cited 2,877 times in the field of pediatric neurology.His clinical expertise includes conditions such as homocystinuria, vitamin B12 deficiency anemia, and exocrine pancreatic insufficiency.

professional profiles📖

Education 🎓

Secondary School: Humanity Greco-Latine (June 1972), Collège du Sacré-Coeur, Charleroi, BelgiumHigh School: Université Catholique de LouvainBaccalauréat en Philosophie: Magna cum Laude (June 1975)Doctor of Medicine: Laude (June 1979)

work Experience💼

1988-2002: Pediatric Neurologist, CHC Espérance & Saint Vincent, Liège, Belgium (Full-time)Lecturer: Pediatric Neurology Course for nurses at “School of Sainte-Julienne,” LiègeLecturer: “Medical Approach of Handicap” in Orthopédagogie2003-2024: Pediatric Neurologist, Centre Hospitalier de Luxembourg, Department of Pediatrics (Full-time)Head of Pediatric Neurology Division (2014-2018, 2018-2024)Lecturer: Pediatric Neurology Course for nurses at “Lycée Technique pour Professions de Santé” (2006-2024)

Research Focus

Dr. Scalais has authored numerous peer-reviewed articles, with a focus on pediatric neurology, metabolic disorders, and neonatal brain function. Notable contributions include:Research on phenobarbital’s effects on cerebral blood flow in newbornsStudies on very long-chain acyl-CoA dehydrogenase deficiency as a cause of neonatal sudden infant deathInvestigations into early myoclonic epilepsy linked to CoQ10 deficiencyDiagnostic and prognostic value of evoked potentials in neonatal hypoxiaCase studies on mitochondrial disorders, such as Leigh’s encephalopathy and POLG mutationsHydroxocobalamin dose intensification in early-onset cobalamin metabolism defects

Conclusion

Dr. Scalais based on his , , and . While increasing could further strengthen his profile, his current body of work already demonstrates and .is highly suitable for this awardsignificant contributions to pediatric neurology researchclinical impactinternational collaborationshigh-impact publications, principal investigator roles, and research fundingoutstanding scientific meritlong-term dedication to pediatric neurology

📚Publications to Noted

  • Scalais E, Beharry K, Papageorgiou A, Bureau M, Aranda JV (1992). Effects of phenobarbital on cerebral blood flow in the newborn piglet. Developmental Pharmacology and Therapeutics, 19(1), 10-18. [doi: 10.1159/000457457]

  • Scalais E, Bottu J, Wanders RJ, Ferdinandusse S, Waterham HR, De Meirleir L (2015). Familial very long chain acyl-CoA dehydrogenase deficiency as a cause of neonatal sudden infant death: improved survival by prompt diagnosis. American Journal of Medical Genetics Part A, 167A(1), 211-214. [doi: 10.1002/ajmg.a.36803]

  • Scalais E, Chafai R, Van Coster R, Bindl L, Nuttin C, Panagiotaraki C, Seneca S, Lissens W, Ribes A, Geers C, Smet J, De Meirleir L (2013). Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). European Journal of Paediatric Neurology, 17(6), 625-630. [doi: 10.1016/j.ejpn.2013.05.013]

  • Scalais E, Connerotte AC, Despontin K, Biver A, Ceuterick-de Groote C, Alders M, Kolivras A, Hachem JP, De Meirleir L (2016). Shwachman-Diamond syndrome presenting with early ichthyosis, associated dermal and epidermal intracellular lipid droplets, hypoglycemia, and later distinctive clinical SDS phenotype. American Journal of Medical Genetics Part A, 170(7), 1799-1805. [doi: 10.1002/ajmg.a.37673]

  • Scalais E, Francois A, Nuttin C (1996). [Diagnostic and prognostic value of evoked potentials facing cerebral hypoxia in newborn infants]. Archives de Pédiatrie, 3 Suppl 1, 251s-253s. [doi: 10.1016/0929-693x(96)86058-1]

  • Scalais E, Francois B, Schlesser P, Stevens R, Nuttin C, Martin JJ, Van Coster R, Seneca S, Roels F, Van Goethem G, Lofgren A, De Meirleir L (2012). Polymerase gamma deficiency (POLG): clinical course in a child with a two-stage evolution from infantile myocerebrohepatopathy spectrum to an Alpers syndrome and neuropathological findings of Leigh’s encephalopathy. European Journal of Paediatric Neurology, 16(5), 542-548. [doi: 10.1016/j.ejpn.2012.01.013]

  • Scalais E, Francois-Adant A, Nuttin C, Bachy A, Guerit JM (1998). Multimodality evoked potentials as a prognostic tool in term asphyxiated newborns. Electroencephalography and Clinical Neurophysiology, 108(2), 199-207. [doi: 10.1016/s0168-5597(97)00076-2]

  • Scalais E, Geron C, Pierron C, Cardillo S, Schlesser V, Mataigne F, Borde P, Regal L (2023). Would early versus late hydroxocobalamin dose intensification treatment prevent cognitive decline, macular degeneration and ocular disease in 5 patients with early-onset cblC deficiency? Molecular Genetics and Metabolism, 140(3), 107681. [doi: 10.1016/j.ymgme.2023.107681]

  • Scalais E, Nuttin C, Seneca S, Smet J, De Paepe B, Martin JJ, Stevens R, Pierart F, Battisti O, Lissens W, De Meirleir L, Van Coster R (2007). Infantile presentation of the mitochondrial A8344G mutation. European Journal of Neurology, 14(11), e3-5. [doi: 10.1111/j.1468-1331.2007.01926.x]

  • Scalais E, Osterheld E, Geron C, Pierron C, Chafai R, Schlesser V, Borde P, Regal L, Laeremans H, van Gassen KLI, van den Heuvel LPWJ, De Meirleir L (Under revision). Parenteral Hydroxocobalamin Dose Intensification in 5 Patients with Different Types of Early Onset Intracellular Cobalamin Defects: Clinical and Biochemical Responses. Journal of Inherited Metabolic Disease.

Hanseob Shin | Antimicrobial | Best Researcher Award

Published on by Top Teachers

Dr. HanseobShin | Antimicrobial | Best Researcher Award

Postdoc scholar at University of iowa,United States

Dr. Hanseob Shin is a dedicated environmental microbiologist specializing in tracking environmental contamination, microbial ecology, and antimicrobial resistance in water systems. As a Postdoctoral Fellow at the Center for Health Effects of Environmental Contamination at the University of Iowa, he actively investigates the fate and transport of antibiotic-resistant bacteria in various aquatic environments. His research applies CRISPR spacerome analysis and microbial source tracking to understand the dynamics of contamination sources. With extensive experience in environmental microbiology, Dr. Shin has contributed significantly to identifying antibiotic-resistant genes in wastewater and river systems, improving public health risk assessment. He has authored numerous scientific publications in prestigious journals and actively participates in national and international conferences. Through his research, he aims to develop innovative solutions for mitigating microbial contamination in natural and engineered water systems, promoting environmental sustainability and health protection.

Professional Profile

Scopus Profile

ORCID

Education 🎓

Dr. Hanseob Shin obtained his Ph.D. in Earth Sciences and Environmental Engineering from the Gwangju Institute of Science and Technology, South Korea, in 2022. His doctoral research focused on long-term monitoring of antibiotic resistance genes and bacteria in rivers and wastewater treatment plants, providing valuable insights into microbial contamination dynamics. Before his Ph.D., he earned a Bachelor of Science in Molecular Biotechnology from Chonnam National University in 2015, where he developed a strong foundation in microbial genetics and biotechnology. His academic journey has been marked by a keen interest in microbial ecology, antibiotic resistance, and environmental health. Dr. Shin’s education has equipped him with expertise in advanced microbiological techniques, including metagenomics, CRISPR engineering, and microbial source tracking. His interdisciplinary training bridges environmental science and molecular biotechnology, enabling him to address pressing challenges in water quality management and public health protection.

Work Experience 💼

Dr. Hanseob Shin has accumulated extensive experience in environmental microbiology and microbial source tracking. Since 2022, he has been a Postdoctoral Fellow at the Center for Health Effects of Environmental Contamination at the University of Iowa, where he investigates antimicrobial resistance in water systems. Prior to this, he worked as a Postdoctoral Research Associate at the Gwangju Institute of Science and Technology, contributing to research on microbial contamination in wastewater treatment plants. His work has involved the application of molecular and genomic tools to study antibiotic-resistant bacteria in environmental settings. Additionally, he has collaborated with government agencies and research institutions to assess microbial contamination in agricultural and urban water sources. Through his academic and research roles, Dr. Shin has developed a strong expertise in microbial ecology, CRISPR-based bacterial identification, and the environmental impact of antibiotic resistance genes.

Research Interests 🔬

Dr. Hanseob Shin’s research is centered on environmental microbiology, microbial ecology, and the fate and transport of antimicrobial resistance in water systems. He investigates the spread of antibiotic-resistant bacteria in aquatic environments, including wastewater treatment plants, rivers, and agricultural runoff. His work utilizes CRISPR spacerome analysis for strain-level bacterial identification and microbial source tracking to trace contamination origins. Dr. Shin also explores the role of core antibiotic resistance genes as indicators of pollution in wastewater and natural water bodies. His studies contribute to improving strategies for mitigating microbial risks in water systems. Additionally, he examines the genetic diversity of antibiotic-resistant bacteria, aiming to understand their persistence and potential health risks. His research has practical applications in public health, environmental policy, and water treatment technologies, promoting safer water resources and sustainable environmental management.

Awards & Achievements 🏆

Dr. Hanseob Shin has received recognition for his outstanding research contributions in environmental microbiology. In 2022, he was awarded the Outstanding Best Poster Award at the International Symposium and Annual Meeting of the KSABC for his work on antibiotic resistance genes in effluent and receiving water. His research projects have secured significant funding, including a $300,000 grant from the Chicago Community Trust for studying antibiotic-resistant bacteria in Iowa’s concentrated animal feeding operations (CAFOs). He has also received substantial research grants from the Rural Development Administration and the Korea Environmental Industry & Technology Institute for projects related to wastewater treatment and antibiotic-resistant organisms. His contributions as a peer reviewer for high-impact journals further highlight his expertise in the field. Dr. Shin’s accolades reflect his dedication to advancing scientific knowledge on microbial contamination and public health.

Conclusion

Dr. Hanseob Shin is a strong candidate for the Best Researcher Award due to his impactful contributions to environmental microbiology, antibiotic resistance, and microbial tracking. His extensive publication record, research funding, and conference presentations position him as an emerging leader in his field. While he could enhance his profile by expanding his independent research leadership and mentorship roles, his current achievements make him a highly competitive nominee for this prestigious award.

Top Noted Publications 📚

Genomic analysis of sewage from 101 countries reveals global landscape of antimicrobial resistance

Authors: Not specified

Year: 2022

Citations: Not specified

Prevalence and Characterization of CRISPR Locus 2.1 Spacers in Escherichia coli Isolates Obtained from Feces of Animals and Humans

Authors: Not specified

Year: 2023

Citations: Not specified

Resistome Study in Aquatic Environments

Authors: Not specified

Year: 2023

Citations: Not specified

Dynamics of Genotypic and Phenotypic Antibiotic Resistance in a Conventional Wastewater Treatment Plant in 2 Years

Authors: Not specified

Year: 2022

Citations: Not specified

Geographical distribution and genetic diversity of Bradyrhizobium spp. isolated from Korean soybean root nodules

Authors: Not specified

Year: 2022

Citations: Not specified

Higher abundance of core antimicrobial resistant genes in effluent from wastewater treatment plants

Authors: Not specified

Year: 2022

Citations: Not specified

Phylogenetic diversity and spatiotemporal dynamics of bacterial and microeukaryotic plankton communities in Gwangyang Bay of the Korean Peninsula

Authors: Not specified

Year: 2022

Citations: Not specified

Emergence of High Level Carbapenem and Extensively Drug Resistant Escherichia coli ST746 Producing NDM-5 in Influent of Wastewater Treatment Plant, Seoul, South Korea

Authors: Not specified

Year: 2021

Citations: Not specified

Metagenomic exploration of antibiotic resistome in treated wastewater effluents and their receiving water

Authors: Not specified

Year: 2021

Citations: Not specified

High genetic diversity of Vibrio parahaemolyticus isolated from tidal water and mud of southern coast of South Korea

Authors: Not specified

Year: 2019

Citations: Not specified

Metagenomic analysis reveals the prevalence and persistence of antibiotic- and heavy metal-resistance genes in wastewater treatment plant

Authors: Not specified

Year: 2018

Citations: Not specified